Medicines &
Healthcare products
Regulatory Agency

National Commission
into the Regulation of
AI in Healthcare

Summary minutes: Third meeting of National Commission into the Regulation of AI in Healthcare (15th December 2025)

Background:

The National Commission into the Regulation of AI in Healthcare was announced on 26 September 2025 as an independent, non-statutory advisory group hosted by the Medicines and Healthcare products Regulatory Agency, (MHRA). Its purpose is to advise on creating a new regulatory framework for AI products in healthcare, supporting the ambition for Great Britian to be the fastest and safest place to regulate AI and software as a medical device.

The Commission will meet monthly until May 2026 and is tasked with publishing recommendations by summer 2026.

Summary of discussion:

- The meeting opened with a welcome from the Chair, who thanked all commissioners for attending. The chair confirmed that all four of the Commission's working groups had recently met to discuss post-market oversight and thanked all working group members for their input and recommendations.

- MHRA's CEO provided an update on an in-person commissioner event which is planned for the new year. They confirmed that the event will take place in either February 2026 or March 2026 and will provide an opportunity to bring commissioners and all working group members together to discuss next steps with the Commission.

- The commissioners considered a paper on the long-term development of AI systems. This included the potential development of Artificial General Intelligence systems, which may be able to operate with the same level of capability as human healthcare professionals in many domains. Commissioners welcomed the paper and agreed that regulation should prepare for the development of these systems now, so they can be deployed quickly and safely.

- The Deputy Chair discussed the Commission's call for evidence. They confirmed that the call for evidence will be published this week (week commencing Monday 15th December) and will be open until Monday 2nd February. Commissioners were asked to promote the call for evidence through their networks once it has opened.

- The Chair then moved the meeting to consider the discussion paper on post-market oversight for AI systems deployed into healthcare settings. The commissioners agreed that the discussion would focus on four main areas: (1) improving access to patient and safety data; (2) clinician liability and feedback loops; (3) healthcare providers' ability to undertake post-market monitoring; and (4) post-market oversight of direct-to-consumer AI systems.

- The commissioners discussed a range of topics and proposals. These included using innovation zones or test beds to build new approaches to post-market oversight, improving feedback loops with healthcare professionals and providers on incidents they report, providers' digital infrastructure and leadership, and the regulatory oversight of direct-to-consumer AI systems.

- The Chair thanked the commissioners for their input and confirmed that the recommendations will be taken forward into policy development and will inform the Commission's final recommendations.

Attendance:

Professor Alastair Denniston (**Chair)**, Professor of Regulatory Science and Innovation, University of Birmingham; Honorary Consultant Ophthalmologist, University Hospitals Birmingham NHS Foundation Trust; Executive Director, Centre of Excellence for Regulatory Science in AI & Digital HealthTech (CERSI-AI)

Professor Henrietta Hughes (**Deputy Chair** and Chair of Health Systems Working Group), Patient Safety Commissioner

Professor Neil Lawrence (Chair of Technology Working Group), DeepMind Professor of Machine Learning, University of Cambridge; Chief Scientist, Trent AI

Professor Cathie Sudlow (Chair of Devolved Authorities Working Group), Head of School of Population Health Sciences, University of Edinburgh and Director of UKRI Adolescent Health Study

Dr Brian Anderson, Chief Executive Officer, Coalition for Health AI (CHAI)

Dame Jennifer Dixon, Chief Executive, The Health Foundation

Adj. Prof. Raymond Chua, Chief Executive Officer, Health Sciences Authority; Deputy Director-General of Health (Health Regulation), Ministry of Health (Singapore)

Dr Paul Goldsmith, Non-Executive Director MHRA; Chair, MHRA's Regulatory and Safety Committee; visiting Professor, Institute of Global Health Innovation, Imperial College London; Consultant Neurologist, Clinical Senate

Dr. Ricardo Baptista Leita, CEO, HealthAI - The Global Agency for Responsible AI in Health

Dr Vish Ratnasuriya MBE, General Practitioner; Chair, Our Health Partnership; Co-Founder, Primary Care Accelerator; Honorary Associate Professor, University of Birmingham

Dr Gabriella Spinelli, Director, RADIANT-CERSI Centre for Regulatory Science & Innovation in Digital Health & Healthcare AI, Brunel University London

Dr Barry Stein, Chief Clinical Innovation Officer; Chief Medical Informatics Officer; Founder, Center for AI Innovation in Healthcare; Attending Vascular and Interventional Radiologist, Hartford HealthCare, Connecticut, USA

Mr Richard Stubbs, Chief Executive, Health Innovation Yorkshire & Humber

Professor Richard Susskind CBE KC, President of the Society for Computers and Law, Special Envoy for Justice and AI to the Secretary General of the Commonwealth